Live Breaking News & Updates on Allogene Therapeutics Daily|Page 4

Stay updated with breaking news from Allogene therapeutics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Nova Scotia , Dimensional Fund Advisors , Royal Bank , Oppenheimer Co , Blackrock Inc , Jpmorgan Chase Co , Alphacrest Capital Management , Allogene Therapeutics Inc , Metlife Investment Management , Allogene Therapeutics , Get Free Report , Marketbeat Ratings , Crest Capital Management , Life Investment Management , Fund Advisors , Therapeutics Stock Down , Get Free , Allogene Therapeutics Daily ,

Allogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by HC Wainwright

Allogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Goldman Sachs Group Inc , Vanguard Group Inc , Allogene Therapeutics Company Profile , Royal Bank , Millennium Management , Allogene Therapeutics Inc , Jpmorgan Chase Co , Allogene Therapeutics , Free Report , Moderate Buy , Street Corp , Sachs Group , Get Free Report , Allogene Therapeutics Daily ,

Allogene Therapeutics (NASDAQ:ALLO) vs. Tenaya Therapeutics (NASDAQ:TNYA) Financial Analysis

Allogene Therapeutics (NASDAQ:ALLO) vs. Tenaya Therapeutics (NASDAQ:TNYA) Financial Analysis
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , South San Francisco , Allogene Therapeutics Inc , Tenaya Therapeutics Inc , Pfizer Inc , University Of Texas Md Anderson Cancer Center , Notch Therapeutics Inc , Allogene Therapeutics , Get Free Report , Tenaya Therapeutics , Given Tenaya Therapeutic , Tenaya Therapeutic , Notch Therapeutics , Cancer Center , Foresight Diagnostics , In Vitro Diagnostic , Allogene Therapeutics Daily ,

JPMorgan Chase & Co. Trims Allogene Therapeutics (NASDAQ:ALLO) Target Price to $8.00

Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its target price decreased by JPMorgan Chase & Co. from $9.00 to $8.00 in a research note published on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other equities research analysts also recently weighed in on the […] ....

United States , Deborahm Messemer , American International Group Inc , Voya Investment Management , Allogene Therapeutics Company Profile , Allogene Therapeutics Inc , Jpmorgan Chase Co , Royal Bank , Securities Exchange Commission , Allogene Therapeutics , Free Report , Moderate Buy , Therapeutics Trading Down , Director Deborah , Exchange Commission , International Group , Investment Management , Howard Capital Management , Get Free Report , Allogene Therapeutics Daily ,

MBB Public Markets I LLC Reduces Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

MBB Public Markets I LLC Reduces Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Deborahm Messemer , Exchange Commission , Jpmorgan Chase Co , Millennium Management , Pricet Rowe Associates Inc , Mbb Public Markets , Public Markets , Allogene Therapeutics Inc , Allogene Therapeutics , Free Report , Street Corp , Director Deborah , Therapeutics Stock Down , Allogene Therapeutics Daily ,